Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The burden of atrial fibrillation (AF) is increasing worldwide; however, most existing data on AF epidemiology are from Western regions. According to our analyses, the estimated absolute prevalence of AF in the Asia–Pacific region in 2023 was approximately 80 million, which is much higher than has been calculated for other global regions.
John C. Lin and colleagues explore the history of racial disparities in cardiovascular outcomes and discuss the landmark findings of the CARDIA study and its contribution to the minority stress model.
The 20th anniversary of Nature Reviews Cardiology comes at a time of exciting innovation for cardiovascular research and clinical cardiology, with the advent of nucleic acid-targeted therapeutics, applications of artificial intelligence, promotion of a healthy cardiovascular exposome, personalization of medicine, and recognition of the importance of diversity, equity and inclusion in health care.
Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.
In the NOTION-3 trial, percutaneous coronary intervention reduced the occurrence of major adverse cardiac events compared with conservative treatment in patients who were undergoing transcatheter aortic valve implantation for severe aortic stenosis and who had stable coronary artery disease.
In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an assist device or stroke at 1 year after the procedure, according to findings from the MATTERHORN trial.
The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress 2024.
A single combined measurement of high-sensitivity C-reactive protein, LDL-cholesterol and lipoprotein(a) levels in plasma predicts incident cardiovascular events among women over a 30-year follow-up period, according to a new study.
Cardiomyocytes can activate the type I interferon response in the infarct border zone after myocardial infarction, indicating that the type I interferon pathway, in addition to its well-established role in antiviral responses, is also involved in cardiac injury.
New research suggests that the presence of clonal haematopoiesis is unidirectionally associated with the development of atherosclerosis and that colchicine holds potential therapeutic value.
The immune response is not unlike a game of chess, with white and black pieces playing opposing roles and orchestrating an opening, a middle and an endgame of innate immunity, adaptive immunity and resolution, respectively. After decades of research, the study of atheroimmunology has brought the first therapeutics to the clinic. Can we resynchronize the immune system in atherosclerosis and save the king?
Acute ischaemic stroke induces persistent innate immune memory through epigenetic changes in myeloid progenitors in the bone marrow, and this innate immune training contributes to cardiac remodelling and dysfunction in the long term, according to a new study.
A new study indicates that proteins in the sarcomere complex are stochastically removed and degraded and are replaced by newly translated proteins. Sarcomere turnover occurs at a similar rate within cardiomyocytes and across the heart and slows with ageing.
Preliminary experience with the use of transcatheter aortic valve implantation (TAVI) to treat non-calcific aortic regurgitation has raised concerns about the short-term effectiveness of TAVI in this setting. A deeper understanding of the interaction between transcatheter heart valves and anatomy in patients with non-calcific aortic valve disease, coupled with the introduction of dedicated TAVI devices, is providing new opportunities in the management of this condition.
The advent of pulsed-field ablation — a series of ultra-rapid, high-energy pulses that result in non-thermal cell death via electroporation — is revolutionizing the field of atrial fibrillation ablation. Data on first iterations of the technology indicate that safety and efficacy are at least similar to that of thermal ablation but with meaningfully shorter procedure duration.
In this Tools of the Trade article, Berkeley and Thomson describe the use of a minimally invasive strategy to standardize the induction of myocardial infarction in mice.
In this Tools of the Trade article, Jablonska describes the use of proximity-based labelling for the proteomic profiling of novel protein–protein interactions.
